Cefotaxime is a third-generation cephalosporin antibiotic with broad-spectrum antibacterial activity. It is most commonly prescribed for the treatment of infectious diseases induced by Gram-positive or Gram-negative bacteria[1].
Cefotaxime (200, 400, 600, or 1000μg/mL; 24h) significantly promotes ROS generation in HT1080 cells[1]. Cefotaxime (0.02-2µg/ml, 5h) combined with Mecillinam could eliminate both cephalosporin-resistant bacteria harbouring CTX-M-15WT and mecillinam-resistant bacteria harbouring the mutant CTX-M-15N135D, thereby constraining resistance evolution of β-lactamase CTX-M-15[2].
Cefotaxime (200 or 400mg/kg/8h, 9 injections, subcutaneous injection) significantly increased bacterial clearance from the pneumonia model in leukopenic mice[3]. Cefotaxime (100mg/kg/4h, 24h, subcutaneous injections) combined with Amoxicillin-Clavulanate significantly reduces bacterial counts and achieves kidney sterilization in in a Murine Urinary Tract Infection Model[4].
References:
[1] Yamada M, Suzuki M, Noguchi T, et al. The antibiotic cefotaxime works as both an activator of Nrf2 and an inducer of HSP70 in mammalian cells. BPB reports. 2020;3(1):16-21.
[2] Rosenkilde CE, Munck C, Porse A, et al. Collateral sensitivity constrains resistance evolution of the CTX-M-15 β-lactamase. Nature communications. 2019 Feb 6;10(1):618.
[3] Sauve C, Azoulay-Dupuis E, Moine P, et al. Efficacies of cefotaxime and ceftriaxone in a mouse model of pneumonia induced by two penicillin-and cephalosporin-resistant strains of Streptococcus pneumoniae. Antimicrobial agents and chemotherapy. 1996 Dec;40(12):2829-34.
[4] Rossi B, Soubirou JF, Chau F, et al. Cefotaxime and amoxicillin-clavulanate synergism against extended-spectrum-β-lactamase-producing Escherichia coli in a murine model of urinary tract infection. Antimicrobial Agents and Chemotherapy. 2016 Jan;60(1):424-30.
Cefotaxime是一种具有广谱抗菌活性的第三代头孢菌素类抗生素。它最常用于治疗革兰氏阳性菌或革兰氏阴性菌引起的传染病[1]。
Cefotaxime（200、400、600或1000μg/mL，24小时）显著促进HT1080细胞中的ROS生成[1]。Cefotaxime（0.02-2µg/ml，5h）与Mecillinam联合应用，可以同时消灭携带CTX-M-15WT的头孢菌素耐药菌和携带突变体CTX-M-15N135D的Mecillinam耐药菌，从而抑制β-内酰胺酶CTX-M-15的耐药性进化[2]。
Cefotaxime（200或400mg/kg/8小时，9次注射，皮下注射）显著增加白细胞减少小鼠的肺炎模型中的细菌清除率[3]。Cefotaxime（100mg/kg/4h，24h，皮下注射）与Amoxicillin-Clavulanate联合使用，在小鼠尿路感染模型中显著降低细菌数量并实现肾脏消毒[4]。